Neurofix Pharma is a Spanish biotechnology company that develops a drug to alleviate the pain suffered by people with spinal cord injuries and improve their quality of life. Este fármaco, el NFX88, se encuentra en la recta final del ensayo clínico IIA y representa una alternativa pionera que busca llenar el vacío que hay en los tratamientos actuales.

Since its birth in 2015, Neurofix Pharma has received the support and recognition of various institutions to advance its clinical program. Obtaining seals such as ‘Best NEOTEC line Company’, ‘Innovative SME’ and ‘Excellence of the EU Horizon 2020’, in addition to the support of Enisa, Iberaval, ICO and European SME, among others, stands out. The company also has important investors, among which the Family Office of the Matutes family stands out.

It should also be noted that to complete phase IIA, aid has been co-financed by the European Regional Development Fund with the aim of promoting research, technological development and innovation for an amount of €117,214.81 through the call for grants from the Institute for Business Competitiveness of Castilla y León, in line 2018 R&D PROJECTS. Project title: Research and development to complete a phase IIA and development of a phase IIB/III clinical protocol with NFX88 for the treatment of neuropathic pain in patients with spinal cord injury (File No.: 04/18/sa/0222).

Product under development

The progress of the clinical trial of NFX88 has allowed the integration of Neurofix in the training program Pre-Market Environment (EpM), of Bolsas y Mercados Españoles (BME), as a previous step to the company’s jump to the capital markets. Neurofix has achieved the support of public bodies such as CDTI, ENISA, ICO, IBERAVAL or ICE (Institute for Business Competitiveness, of the Junta de Castilla y León).

NFX 88, a modified oleic acid molecule anti-inflammatory drug with GPCR-G protein uncoupling activity.The effects of NFX88 on hyperalgesia reduction, which is a common condition in neurological disorders and neurodegenerative diseases, will be studied. NFX88 is formulated for convenient oral administration. NFX88 is formulated for convenient oral administration. A Phase IIA clinical trial for neuropathic pain in patients with spinal cord injury has been completed with excellent results